Akthelia Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Akthelia is a late preclinical stage biopharma company addressing mucositis — a toxic effect of chemo and stem cell transplant conditioning that compromises gut integrity, drives microbial translocation, and directly contributes to preventable deaths. Supported by leading global KOLs, Akthelia is developing AKT-011, a first-in-class oral immunomodulator that preserves epithelial barrier function and prevents downstream complications. With a clearly defined regulatory path, a high-incidence initial indication in multiple myeloma, and CTA-enabling studies planned, AKT-011 is positioned to become the first approved therapy for mucositis — improving survival, reducing hospital burden, and setting a new standard in supportive oncology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}